Table 3 Grade group at diagnosis by treatment groups and AR copy number status.

From: Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

First line mCRPC

n (%)

AR copy number

Normal

Gain

Not available

Docetaxel, N

Grade group 2–4

74 (66.7)

32

15

27

Grade group 5

37 (33.3)

15

8

14

Abiraterone, N

Grade group 2–4

44 (71.0)

26

4

14

Grade group 5

18 (29.0)

7

2

9

Enzalutamide, N

Grade group 2–4

47 (68.1)

35

4

8

Grade group 5

22 (31.9)

11

5

6

  1. mCRPC metastatic castration-resistant prostate cancer, AR androgen receptor, n number.
Back to article page